LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Dataset of Plasma Cells to Aid Diagnosis of Multiple Myeloma

By LabMedica International staff writers
Posted on 06 Feb 2025
Image: The plasma cell dataset was created to assist in the accurate diagnosis (Photo courtesy of Shutterstock)
Image: The plasma cell dataset was created to assist in the accurate diagnosis (Photo courtesy of Shutterstock)

Myeloma is a rare blood cancer that originates in plasma cells, a type of immune cell responsible for producing antibodies that help fight infections. The disease begins when an abnormal plasma cell starts to uncontrollably divide in the bone marrow — the soft tissue found inside bones — leading to the production of large numbers of genetically identical, abnormal cells. These cells, known as clonal cells, do not function as normal plasma cells would. Instead, they crowd out healthy blood cells in the bone marrow, disrupting their growth. When myeloma affects more than one bone marrow site, which is typically the case, it is referred to as multiple myeloma (MM). To confirm a diagnosis of myeloma, doctors perform a biopsy, which involves collecting a sample of bone marrow cells. If myeloma is present, at least 10% of the cells in the sample will be abnormal plasma cells. This sample is usually analyzed manually by an expert, who examines the tissue under a microscope and counts the cells. However, this process is time-consuming and labor-intensive, requiring significant resources. Additionally, inconsistencies in the interpretation of results can occur, affecting the diagnostic accuracy, depending on the evaluator’s expertise. This can be particularly challenging in regions with fewer trained professionals.

To address these issues and enhance the myeloma diagnostic process, researchers from the Federal University of Bahia Institute of Computing (Salvador, Brazil) have developed a large dataset of bone marrow cells from patients with MM and other blood disorders. This dataset, named PCMMD (Plasma Cells for Multiple Myeloma Diagnosis), was created to assist in the accurate diagnosis of MM. The data was collected from individuals diagnosed and treated within the Brazilian Public Health System. Thousands of bone marrow cells from these patients were photographed using a smartphone camera after being visualized under a microscope. Hematologists, experts in blood disorders, then manually analyzed the images, labeling the cells as either plasma or non-plasma cells. The researchers believe that this dataset could improve the efficiency and accuracy of diagnosing MM, especially in resource-limited areas where trained experts are scarce.

In addition to helping doctors with less experience identify myeloma cells, the researchers hope their dataset will serve as a foundation for developing AI-based systems that can automatically distinguish plasma cells from non-plasma cells. Such advancements, they noted, could enhance the diagnostic process for all clinicians and ultimately benefit patients. To test the potential of their dataset, the researchers used it to train an AI-based algorithm to recognize plasma and non-plasma cells in bone marrow samples. The results, published in Scientific Data, showed that the model performed well, correctly classifying cells. The disease status predicted by the AI model matched the diagnosis made by an expert for nine out of ten patients. Given the simple, smartphone-based methodology, the scientists highlighted that this approach could be easily implemented even in resource-constrained environments. The team aims for their dataset to be widely available, encouraging other researchers to build upon it and develop even more advanced AI models to improve myeloma diagnosis.

“Considering all analyses … we are confident that our dataset contains valuable patterns to identify plasma and non-plasma cells, providing an important and low-cost setup to support hematologists,” the researchers wrote. “The availability of our dataset and benchmark model support ongoing research and development in the field, promoting continuous improvement in the accuracy and efficiency of MM diagnostics.”

Related Links:
Federal University of Bahia Institute of Computing 

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Urine Chemistry Control
Dropper Urine Chemistry Control

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more